Ali Saeed, MD
Pulmonary Disease · Phoenix, AZNPI 1750581641
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (50.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 85.6% of it on its own, with 19 other manufacturers making up the rest. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $703.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$118K
- Serpex Medical Inc$17K
- Pulmonx Corporation$2K
- Galvanize Therapeutics, Inc$237
- Olympus America Inc.$235
- Astellas Pharma US Inc$175
- plus $722 from 14 others
Across 9 payments — averaging $8313.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$45K
- Serpex Medical Inc$30K
What the payments were for
- Consulting fees$16,00012%
- Speaking & faculty fees$34,55025%
- Travel & lodging$9,9427%
- Food & beverage$7,5415%
- Education$69,67551%
- Gifts$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 146 | $117,971 |
| Serpex Medical Inc | 4 | $16,698 |
| Pulmonx Corporation | 10 | $1,806 |
| Galvanize Therapeutics, Inc | 2 | $237 |
| Olympus America Inc. | 14 | $235 |
| Astellas Pharma US Inc | 2 | $175 |
| Merit Medical Systems Inc | 2 | $106 |
| Sanofi | 1 | $94 |
| Imbio Inc. | 1 | $90 |
| Actelion Pharmaceuticals US, Inc. | 2 | $84 |
| Medtronic | 1 | $62 |
| Davol Inc. | 1 | $57 |
| AstraZeneca | 2 | $56 |
| Pfizer | 2 | $35 |
| Vapotherm Inc | 1 | $28 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Atricure, Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| United Therapeutics Corporation | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$137,845 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $24,261 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $176 |
| Levofloxacin | 16 | $144 |
| Prednisone | 18 | $56 |
| Azithromycin | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ramit SharmaPhoenix$65K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.